Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients
Izadi M, Tahmasebi S, Pustokhina I, et al. Multiple Sclerosis and Related Disorders, 2020.
- Study type
- Cohort study
- People studied
- 20 people
- Population
- Multiple sclerosis patients
- Published
- 2020, Multiple Sclerosis and Related Disorders
- Identifiers
- PMID 32862036, DOI 10.1016/j.msard.2020.102466
What the authors reported
In 20 MS patients, the authors' own "non-controlled study" found ozone autohemotherapy lowered the frequency of pro-inflammatory Th17 cells and related markers after treatment compared with before.
What limits this result
The authors describe it as non-controlled; a before-after comparison in one treated group measuring a laboratory immune marker rather than disability or symptom outcomes.
How ozone acts on blood and cells, how blood filters work, and studies that measure markers in the blood rather than how patients fare. None of these shows whether EBO2 helps patients. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Autoimmune Conditions: Rheumatoid Arthritis, MS, Lupus and the Evidence
What the ACR rheumatoid arthritis guideline and small ozone autohemotherapy studies actually show about EBO2 (also called EBOO) for autoimmune disease.